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Abstract
Cancer cells, stem cells and cancer stem cells have for a long time played a significant role in the biomedical
sciences. Though cancer therapy is more effective than it was a few years ago, the truth is that still none of the
current non-surgical treatments can cure cancer effectively. The reason could be due to the subpopulation called
“cancer stem cells” (CSCs), being defined as those cells within a tumour that have properties of stem cells:
self-renewal and the ability for differentiation into multiple cell types that occur in tumours.
The phenomenon of CSCs is based on their resistance to many of the current cancer therapies, which results in tumour
relapse. Although further investigation regarding CSCs is still needed, there is already evidence that these cells may
play an important role in the prognosis of cancer, progression and therapeutic strategy. Therefore, long-term patient
survival may depend on the elimination of CSCs. Consequently, isolation of pure CSC populations or reprogramming of
cancer cells into CSCs, from cancer cell lines or primary tumours, would be a useful tool to gain an in-depth
knowledge about heterogeneity and plasticity of CSC phenotypes and therefore carcinogenesis. Herein, we will discuss
current CSC models, methods used to characterize CSCs, candidate markers, characteristic signalling pathways and
clinical applications of CSCs. Some examples of CSC-specific treatments that are currently in early clinical phases will
also be presented in this review.
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Background
Despite years of intensive experimental efforts and de-
velopment of several novel treatment strategies, cancer
is still a leading cause of mortality. New knowledge of
the fundamental mechanisms underlying initiation of
carcinogenesis can lead to a dramatic shift in the field of
cancer research and treatment. This innovative under-
standing combines cancer and stem cell biology. The
hypothesis that cancer is caused by the expansion of a
population of cells with stem cell characteristics has
attracted considerable attention [1–3]. The model sug-
gests a hierarchical organization of tumour cells, with
self-renewal and differentiation abilities, that are capable
of regenerating a new tumour in vivo with the same het-
erogeneity as the primary tumour [1]. This type of cells,
identified as CSCs or tumour-initiating cells, possess un-
restrained proliferative abilities, resistance to apoptotic
cues, and aptitude to establish tumours in immunodefi-
cient mice [4, 5]. The cellular hierarchy was first identi-
fied in hematopoietic malignancies such as myelogenous
leukaemia [6, 7], and later on in solid tumours [4], based
on the expression of specific cell surface molecules.
CSCs have been reported to be resistant to conven-
tional chemo- and radio-therapy [8, 9]; therefore, novel
therapies integrating the current oncologic treatments
should be identified and developed. The existing therap-
ies generally target highly replicating cancer cells that
constitute the bulk of the tumour but may not eradicate
CSCs. For this reason, instead of trying to eliminate the
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bulk of the tumour or reduce its size, development of
therapies aiming to eradicate the resistant CSCs would
be a more efficient and rational approach [10]. Further-
more, it is important to identify and characterize CSCs
in order to improve our knowledge about the biology of
the tumour and carcinogenesis.
Identification of CSCs is a complex process and it re-
lies on different strategies: expression of specific surface
markers, in vitro assays such as anchorage-independent
growth assays (tumour sphere assays) and in vivo limit-
ing dilution assays, among others [11]. In this review, we
will summarize the most recent cell-based in vitro
models of CSCs and the promising clinical applications
derived from these models, from biomarker discovery
and microenvironment analysis to the identification of
novel oncologic targets and therapies.
History and current view of the CSC concept
The CSC model suggests that a subset of cancer cells
displaying self-renewal and pluripotency properties is re-
sponsible for the regeneration of malignant tissues and
their homeostasis [10].
In 1875 Cohnheim proposed the first CSC hypothesis,
also called the “embryonal-rest theory”, that suggested
the presence of embryonic-like cancerous cell remnants
in adult tissues which develop into cancer in a non–
spontaneous way [12]. In 1994 Dick and colleagues dem-
onstrated that leukaemia initiating stem cells (LSCs),
present in the blood of leukaemia patients, may induce
acute myelogenous leukaemia (AML) when transplanted
into severe combined immunodeficient (SCID) mice [6].
This was the first experimental evidence in support of
the CSC theory, demonstrating the existence of cancer
stem-like cells. A broad spectrum of cell surface stem
cell markers (e.g. CD133, CD44, and CD24) allowed the
identification of CSCs in human solid tumours, includ-
ing brain, breast, prostate, pancreas, liver, ovary, skin
and colon cancers, and melanoma [13–20] (Fig. 1).
Recently, two models that illustrate the organization of
CSCs within the tumour have been proposed. According
to the “stochastic model” (or “clonal evolution model”),
initially described by Nowell and colleagues, every cancer
cell in the tumour could gain the ability to self-renew and
differentiate to the numerous and heterogeneous lineages
of cancer cells that compromise the tumour. In this way,
they were capable of repopulating the entire tumour [21].
On the other hand, the “hierarchy model” is based on the
assumption that every tumour is a heterogeneous con-
glomerate of cancer cells and only a minority of them pos-
sess CSC properties [22].
During the past years, the origin of CSCs has been the
centre of investigation, and in most cases it remains un-
known and controversial, as shown by different studies
on LSCs [23, 24]. The identification of CSCs origin is
very complex as the process of malignant transformation
into CSCs may occur in different stages and within a
very limited subpopulation of cells, therefore difficult to
reach and study in detail. Nonetheless, the literature
suggests adult stem and/or progenitor cells as the poten-
tial cell of origin of CSCs [10]. Adult stem cells are long
lived cellular reservoirs with the mission to replenish
damaged/senescent cells contributing to tissue homeo-
stasis. According to Feinberg’s “epigenetic progenitor
model of human cancer” these cells live long enough to
accumulate genetic and epigenetic changes that help
them rearrange their microenvironment in such a way
so that they can promote the origin of CSCs [25].
Normal adult stem cells have an ability to immortalize
themselves via self-renewal and to generate mature cells of
appropriate tissue through differentiation. Biology of stem
cells is a relevant source of knowledge for cancer studies
because of the similarities in the mechanisms that regulate
self-renewal of normal (adult) stem and cancer cells [26].
Indeed, normal adult stem cells and CSCs share many char-
acteristics. In addition to i) self-renewal and differentiation
properties via asymmetric division, ii) CSCs and adult stem
cells rely on the same signalling pathways; like Wnt, Hedge-
hog, Notch, among others, to control self-renewal, iii) they
have similar metabolism (showing preference to oxidative
glycolysis), iv) they express ATP-binding cassette (ABC) ef-
flux transporters that protect cells from toxic compounds,
v) express similar surface markers such as CD133 and
CD44, vi) have enhanced anti-apoptotic, DNA-repair and
oxidative stress-protective mechanisms, vii) exhibit a slow-
cycling phenotype related to a quiescent state, viii) have
similar genetic and epigenetic profiles, ix) have extended
telomeres, and x) exhibit long life spans [27, 28].
In order to comprehend the connection between CSCs
and normal stem cells, the transcriptional program in in-
testinal stem cells and colorectal carcinoma [29], as well
as lung stem cells and lung CSCs [30], were studied. Inter-
estingly, both studies revealed a significant overlap in the
gene expression profiles between the two types of cell
populations, mainly associated with self-renewal, angio-
genesis, migration, and anti-apoptosis. Moreover, some
proteins highly expressed in embryonic stem cells (ESCs),
such as PRC2-regulated genes and the transcription fac-
tors Klf4, Nanog, Oct4, and Sox2, are frequently present
in poorly differentiated tumours with adverse clinical out-
come [31, 32]. The importance of Nanog and Oct4 in can-
cer research is supported by the elevated expression of
these transcription factors in lung and ovarian cancer
cells, which results in drug resistance and promotion of
the epithelial-mesenchymal transition (EMT) [32, 33].
Moreover, some groups suggest that CSCs could also ori-
ginate from more committed progenitors that acquire
stemness-related features as an effect of accumulation of
epigenetic and/or genetic changes [34, 35].
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Metastasis, and not the primary tumour itself, is usually
the main cause of death in cancer patients. Metastasis de-
mands that cancer cells detach from the primary tumour
site, travel systemically and form new tumours elsewhere
in the body. Metastasis in cancer might be associated with
the existence of a subpopulation of CSCs which initiate
the formation of secondary tumours in distant organs and
promote their proliferation, followed by the recruitment
of new vasculature, or angiogenesis [36]. Although the
current knowledge about the association of CSCs with
metastasis is low, recent evidence supports the idea that
EMT markers, known to be implicated in tumour cell mi-
gration, are expressed in CSCs [37]. These cells might be
the precursors of the metastatic CSCs. Cancer cells might
lose their epithelial characteristics by lack of polarity or
intercellular adhesion, and gain mesenchymal properties
followed by migration to different parts of the body [38].
In 2004 Yang and colleagues proposed EMT as being a re-
quired step in breast cancer metastasis [39]. In Scheel et
al. (2011), the authors suggest that any given normal or
neoplastic epithelial cell type utilizes the same network of
paracrine and autocrine signals from the microenviron-
ment in order to reach a certain EMT potential and main-
tain itself in a mesenchymal stem cell state with enhanced
metastastic properties. In transplantation assays this is
manifested by an increase of mammosphere forming cells
with CD44+CD24- phenotype [40]. Many different genetic
and epigenetic modifications contributing to adult stem
and progenitor cell homeostasis can subsequently repro-
gram these cells to acquire some features that in
conjunction with a potential “tumour promoting environ-
ment”, may lead to cancer cells and CSC formation [3].
Proper elimination of CSCs might avoid cancer recur-
rence, and therefore, it is important for a successful can-
cer therapy. Indeed, CSCs are resistant to anti-tumour
therapies, which preferentially eliminate cells with more
differentiated phenotypes. This results in surviving CSCs
that are responsible for tumour recurrence [41, 42]. The
most important evidence supporting the critical role of
CSCs in tumour regeneration has emerged from breast
cancer studies. In this type of cancer up to 25 % of re-
currences may appear after 10 years of the first success-
ful therapy, and these cancers still have the properties
similar to the primary tumours [43, 44]. This observa-
tion can be related with the presence of a small popula-
tion of surviving CSCs more resistant to anti-tumour
treatments than non–stem cancer cells that may be re-
sponsible for tumour relapse after initial successful ther-
apy [9]. In a more recent study it was described that
breast cancer metastasizes in bone marrow, where it ac-
quires characteristics of slow cycling cells with enhanced
chemoresistance and gap junctional intercellular com-
munication (GJIC) common with the stroma [45].
Cell-based models of CSCs
Approaches to isolate the cancer stem-like cell
population
Detection and quantification of CSCs can be carried
out through in vivo or in vitro assays. The introduc-
tion of cells either from human primary tumours or
Fig. 1 Most common cell surface markers currently used to identify CSC subpopulations from different types of cancer
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cancer cell lines into immunodeficient mice, like non-
obese diabetic severe combined immunodeficient
(NOD/SCID) mice, offers a sensitive system to iden-
tify CSCs. Although this system is commonly used, it
has some weaknesses, such as short life span of the
mouse models, inadequacy of the CSC-specific cyto-
kines and NK-driven residual innate immunity and
failure to represent the tumour or disease microenvir-
onment [46].
Quintana was first able to show that he can dramatic-
ally increase the sensitivity of the assay in recognizing
CSCs by employing a “modified xenotransplantation
assay”, such as the NOD scid gamma (NSG) mice, which
lack the interleukin-2 receptor gamma chain [47]. With
this model, almost 25 % of melanoma cells from patients
were able to form new tumours in vivo. This implies that
CSCs may not be as rare as previously estimated,
highlighting at the same time the vital role of micro-
environment in supporting tumour growth. Using this
approach, Ishizawa et al. (2010) determined that the fre-
quency of CSCs in many tumours is up to 10-fold higher
in NSG mice, but generally it remained low (less than
0.04 %) overall [48]. Similarly, Kuperwasser and col-
leagues employed genetically modified mouse models for
breast cancer growth and metastasis, showing that
species-specific stromal-niche interactions are critical for
the in vivo growth and osteotropic metastasis of CSCs
[49]. More “humanized” murine models should be
employed in the future, which will be more permissive
of implanted human cells to reconstitute their natural
microenvironment [50].
By being a rare population within the tumour tissue,
CSCs are difficult to isolate and study, which limits our
ability to monitor the development and the pathogenesis
of the cancer. This issue makes it necessary to develop
cell-based models of cancer stem-like cells. Many in vitro
assays for detection and identification of CSCs have been
used, though a non-universal method can be applied [51].
The application of these CSC in vitro models has many
benefits as it would permit the increment of our know-
ledge about CSCs, together with tumour biology, micro-
environment, carcinogenesis, biomarker discovery, and
could lead to improvement and progress of oncologic
therapies, among other applications.
Recently published literature has employed different
in vitro approaches to reach the CSC population. Ac-
cording to these publications, CSCs can be mainly
obtained from cancer cell lines or primary tumours
through i) reprogramming [32, 52–69], ii) the expres-
sion of specific surface markers [15, 70, 71], iii) de-
tection of the side population [72–78], iv) selection of
cells resistant to anoikis [79], v) or based on the ap-
plication of specific culture conditions, among other
techniques [80–83].
Reprogramming of cancer cells as a way to model cancer
Current cancer models are not sufficient to tackle the
heterogeneity of human cancers. Animal models of can-
cer have been used for decades however, distinctions are
observed between animal and human cancers. Cancer
cell lines, although inexpensive and immortal, do not
represent the primary tumour and disease progression,
and they cannot easily be replaced by the primary cells
isolated from tumours, that are limited and complex to
maintain. In this way, in vitro models of carcinogenesis
derived from reprogramming patients’ cancer cells offer
promise for the deciphering of the early mechanisms of
the development and progression of cancers from pluri-
potent cells [84].
Historically, reprogramming back to pluripotency in-
volved either blastocyst injection [85], or nuclear transfer
(NT) [86], or lately, the exogenous forced expression of
specific sets of transcription factors, known as “induced
pluripotent stem cell (iPSC) technology” [32, 52–69] (see
Table 1 for more details).
Similarly to normal somatic cells, human cancer cells
have of late been successfully reprogrammed into a pluri-
potent state, as shown for gastrointestinal [57–60, 69],
breast [62–64, 87], prostate [65], bone [61], liver [56], and
lung [32, 54, 55] cancers, melanoma [52, 53, 88], and leu-
kaemia [66–68]. By introducing nuclei from mouse mel-
anoma cells into enucleated oocytes, Hochedlinger and
colleagues (2004) established ESC lines from blastocysts,
proving that cancer cells can be reprogrammed into a
stem state disregarding the genetic aberrations. These
ESCs had the potential to generate teratomas and to form
chimeras that develop high penetrance melanomas [88].
Similarly, Blellock and colleagues were able to generate
NT-derived ES cell lines from human embryonal carcin-
oma (EC) cells, with developmental potential similar to
the respective donor EC cells [89].
In 2006 Yamanaka and Takahashi demonstrated that
additionally to NT or blastocyst injection, nuclear repro-
gramming can be achieved by applying iPSC technology.
Yamanaka’s group established a panel of specific transcrip-
tion factors, Oct4, Sox2, Klf4, and c-Myc (OSKM, or
Yamanaka factors), which were previously shown to be
oncogenic, with the ability to induce an ESC-specific gene
expression module into somatic cells, converting them
into pluripotent cells, the iPSCs [90]. This technology has
been updated and applied effectively to somatic cells of
many species, such as mouse [90], rat [91], rabbit [92], pig
[93], rhesus monkey [94], and human [95–97], resulting in
the generation of pluripotent ES-like cells with the cap-
ability to differentiate into cells of the three germ layers
[90]. Similarly to normal somatic cells, malignant cells ei-
ther from cancer cell lines [32, 52–55, 57–64, 66, 98, 99]
or primary tumours [65, 67–69] from several cancer
types have been successfully converted to iPS-like
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cells, or induced pluripotent cancer cells (iPCs) [55,
57, 66, 69] (Table 1).
In the last half-decade many research groups
employed iPSC technology in their research involving
human cancer cells, mainly through the overexpression
of Oct4, Sox2, Klf4, and c-Myc factors [54, 57, 66, 69]
(summarized in Table 1). The obtained reprogrammed
cells are pluripotent as defined by all in vitro and in vivo
criteria used to define pluripotent stem cells generated
from somatic cells [90, 95], i.e. they express ESC
markers, telomerase activity, have self-renewal abilities
and are pluripotent by generating cells of all three germ
layers; as shown by the formation of spheres in vitro,
and teratomas in immunocompromised mice. When
Oct4, Klf4, and c-Myc were overexpressed in a murine
cancer cell line of melanoma, the generated iPCs were
able to form viable chimeric mice after injection into
blastocysts [52].
Although Yamanaka’s set of iPSC factors are the most
commonly used in research, the replacement of c-Myc
and Klf4 with Nanog and Lin28 was implemented to hu-
man fibroblasts by Thomson’s group, as c-Myc may
cause death and differentiation of ESCs [95]. This new
group of transcription factors, together with the overex-
pression of hypoxia-inducible factor (HIF) could convert
lung cancer cells into partially reprogrammed cells cap-
able of generating highly aggressive malignant tumours
when injected into immunocompromised mice [55]. Al-
ternatively, other groups have demonstrated that not all
four transcription factors are required to reprogram can-
cer cells. This conclusion came from analysis of primary
tumour specimens from patients. Chiou et al. (2010)
showed that CD133+ lung CSCs co-express Oct4 and
Nanog when compared to CD133- cancer cells. When
overexpressed in A549 cancer cells, Oct4 and Nanog
induced the formation of cancer stem-like cells and en-
hanced tumorigenesis and metastasis in mice [32]. A
similar approach was used in breast cancer where early
stages of carcinogenesis were linked with Sox2 expres-
sion. When overexpressed alone in a breast cancer cell
line, Sox2 stimulated the formation of spheres in vitro
and tumour in vivo, demonstrating its function in the
pluripotency preservation [62]. In other studies, Sox2
was dispensable in reprogramming of melanoma cells
into iPSCs [52].
Alternative methods of reprogramming, where no in-
tegration in the genome occurs, have been published. In
a study proposed by Ying and co-workers (2008), the
family of microRNA (miRNA) miR-302, highly expressed
in ESCs, was transfected into cancer cells generating ES-
like pluripotent cells with self-renewal and multipoten-
tial differentiation properties [53]. A similar technology
was successfully applied to hepatocellular carcinoma
cells as shown by the group of Mori in 2014 [99]. On
the other hand, reprogramming of cancer cells can be
achieved through the application of small chemical mol-
ecules. When breast cancer cells were treated with
valproic acid (VA), aldehyde dehydrogenase (ALDH)-
positive cells with a superior efficiency of mammosphere
formation and tumorigenic ability were generated [100].
Though the iPSC process has been applied successfully
to cancer cells from both primary tumours and cancer
cell lines, it is time-consuming and less efficient com-
pared to the reprogramming of non-tumorigenic somatic
cells [57, 63, 67, 69, 101]. This observation may be due
to the availability of certain number of cancer cells that
contain a particular genetic and epigenetic status like an-
euploidy or mutations in components involved in the
epigenome [102]. Albeit a lower reprogramming effi-
ciency has been described for cancer cells, some excep-
tions have been observed. Zhang et al. (2013) observed a
slight augmentation of efficiency, probably associated
with loss of pre-existing tumour suppressors [61]. As
shown for normal somatic cells, the improvement of the
reprogramming efficiency can be achieved through the
overexpression of mir-302 [53] or HIF [55], deficiency of
p53 [58] or Ink4/Arf [103], hypoxia [55, 58], or through
the treatment with histone deacetylase (HDAC) inhibi-
tors [e.g. azacitidine (5-azaC)] [104], VA [100], suberoy-
lanilide hydroxamic acid (SAHA), or trichostatin A
(TSA) [105]. When reprogramming factors were
expressed together with HIF in lung cancer cells, the
generated iPCs had enhanced tumorigenesis, showing
the importance of hypoxia in the improvement of the re-
programming efficiency [55]. In 2009 Yamanaka pro-
posed the “stochastic model”, rather than the “elite
model”, to explain the low efficiency observed during
the reprogramming process of normal somatic cells.
Briefly, the “elite model” states the existence of a small
population of cells that can be reprogrammed partially
or completely. Alternately, the “stochastic model” states
that most cells may undergo the process of reprogram-
ming but just a minority completes it [106]. Lai and col-
leagues (2013) assessed this issue in reprogrammed
cancer cells and concluded that the reprogramming
process of these cells may follow the “elite model” [107].
According to the published results, only a small subpop-
ulation of cells was selected for reprogramming as all
obtained iPCs were free of mutations, unlike the paren-
tal cells. The contradictory results between iPSCs and
iPCs may be related with the differences observed be-
tween normal somatic cells and cancer cells.
iPSCs tend to differentiate into the same tissue lineage
from which they originate. Erasure of the epigenetic
memory (methyl-DNA-marks) during factor-based re-
programming seems to be inefficient, leading to the
maintenance of a “residual epigenetic memory” within
the iPSCs [108]. Kim and colleagues performed a high-
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throughput array-based analysis of the methylome of iPS
cells from different sources, in which they observed
DNA methylation signatures reminiscent of the tissue of
origin. Epigenetic memory may explain why blood-
derived iPSCs differentiate with higher efficiency into
blood when compared to fibroblast-derived iPSCs [108].
A similar observation was demonstrated for iPCs, which
tend to generate the cancer type from which they are de-
rived [69]. This can be due to a partial reprogramming
of cancer cells. Although the reprogramming of cancer
cells can generate cells with similar characteristics to
ESCs, as shown by the transcriptome analysis under-
taken by Mahalingam and co-workers [54], iPCs may
not be so similar to ESCs as it was thought. In 2013 the
group of Matushansky published an interesting work
where the degree of differentiation reversion was evalu-
ated after reprogramming sarcoma cells [61]. When the
level of differentiation was compared, the gene expres-
sion and DNA methylation analysis denoted that repro-
grammed sarcomas are closer to sarcomas and to
partially reprogrammed fibroblasts than to fully repro-
grammed fibroblasts and ESCs [61]. Similar conclusions
were drawn by Menendez and colleagues (2013), where
reprogrammed MCF-7 cells were in a status between
differentiated cancer cells and iPSCs [63]. Taken to-
gether, these suggest that reprogrammed cancer cells
seem to reach a “minimum state of differentiation”
which is enough to confer them a pluri-differentiation
potential. Alternatively, as suggested by Nagata et al.
(2012), a pluripotent state may be achieved but not ne-
cessarily an ESC state [81].
Some groups have shown that reprogramming of cancer
cells into a pluripotency state can decrease the tumori-
genic capability of reprogrammed cells compared to par-
ental cells [52, 54, 57]. This observation can be associated
with the epigenetic reset that can drive the downregula-
tion of the mechanisms (i.e. silencing of oncogenes) re-
lated with the tumorigenic behaviour of the cancer cells
[54, 102]. In fact, a study by Wang and co-workers (2012)
demonstrated that reprogrammed lung cancer cells hold a
rectified epigenetic profile that may result in a reduction
of the tumorigenic potential of these cells. The downregu-
lation of genes usually expressed in non-small cell lung
cancer (NSCLC) (e.g. KRT19 and S100P) might be associ-
ated with DNA methylation occurred during reprogram-
ming, indicating the importance of DNA methylation to
tumorigenesis [54]. This characteristic has become of
interest for drug development and therapy. Moreover,
when reprogrammed cancer cells are induced to differen-
tiate into a germ layer diverse of the tissue from which
they are derived, these cells lose the tumorigenic ability in
vivo [61, 109]. Hence, when glioblastoma-initiating cells
were induced to differentiate into a mesoderm lineage, no
malignant brain tumours developed in mice [109]. An
analogous observation was made by Zhang et al. (2013).
When reprogrammed sarcomas were terminally differenti-
ated either into their own or into an alternate lineage of
origin and inoculated in NSG mice, in both cases no tu-
mours were detected [61].
Understanding the transitions among different states
and acquiring the ability to exogenously manipulate the
stemness and/or differentiation of normal but most im-
portantly of tumours may hold promise as a therapeutic
strategy in the near future (Fig. 2). In recent years, in-
duced pluripotent stem cell reprogramming technology
offered the possibility of generating clinically valuable
pluripotent stem cells (named iPSCs) from fully differen-
tiated somatic cells. The same reprogramming strategy is
being now employed on cancer cell lines or patients’ tu-
mours (named induced pluripotent cancer stem cells or
iPCSCs) (blue arrows in Fig. 2). iPCSCs cells epigeneti-
cally and transcriptionally resemble the ESC state and
the cancer genome “seems to be repressed” in the pluri-
potent state. In some cases the iPCSCs may exhibit early
stage phenotypes corresponding to partial expression of
the reprogrammed cancer genome, constituting, in this
way, a live cell model to study cancer progression [84].
Moreover, these iPCSCs have the ability to re-
differentiate (orange arrow in Fig. 2) back to where they
originated or other terminal differentiated cell lineage,
losing along this process their tumorigenic and meta-
static properties [110]. Alternatively, as it was shown in
sarcomas, the induction to more differentiated state can
occur directly from the adult tumour, in this case named
“trans-differentiation” (dashed blue arrow), without the
need to pass first from the pluripotent state [61]. In the
case of sarcomas, it was shown that various types of
sarcomas can be trans-differentiated into multiple ma-
ture connective tissues (dashed blue arrow in Fig. 2),
abolishing their tumorigenic potential as measured by
the ability to further proliferate in vitro (on soft agar) or
in vivo (xenograft formation), without the need to be
reprogrammed first in the ESC state [61]. Similarly, it
was found that the epigenetic switch (mainly tumour
suppressor hypo-methylation) in trans-differentiated
glioblastomas inhibits their tumorigenicity when injected
into mice [102]. Trans-differentiation of cancer cells to
terminal differentiation via addition of chemical agents
i.e. retinoids for acute promyelocytic leukaemia (APL)
[111], peroxisome proliferator activated receptor gamma
(PPARg) agonists for liposarcoma [112], or epigenetic
drugs [113], could potentially be preferable with respect
to clinical application compared to classical factor based
reprogramming.
Other cell-based models of CSCs
Cancer cells with tumorigenic potential can be identified
based on their capacity to form tumours when injected
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into mice. This approach allowed the isolation of the
CSC population from breast tumours based on a specific
phenotype of these cells, CD44+CD24-/low [1]. The idea
to identify CSCs by flow cytometry comes from leukae-
mia where LSCs constitute a population of CD34+CD38-
cells capable of generating leukaemia in immunosu-
pressed mice [114]. The prospect of CSC identification
based on the expression of specific surface markers
opened the way to their detection in other solid tu-
mours: brain and lung (CD133+), prostate, gastric, and
ovarian (CD44+) [13–15] cancers [16, 17], among others
[18–20]. A more detailed description of the current sur-
face markers used to identify CSCs can be found in Fig. 1
[reviewed by Allegra et al. (2014)] [2]. A unique combin-
ation of surface markers has not been identified so far as
their universal application to most cancer types and sub-
types is limited. Despite the fact that CD44 and CD24
are expressed in most tumours and are commonly used
to identify CSCs, they are not specific to all cancers
[115], and in addition, they can be also found in ESCs.
The identification of surface markers specific to CSCs
has allowed their sorting from either cancer cell lines or
primary tumours through cytometric-based technologies
or immunomagnetic beads [70]. In a recent publication,
CD44+CD24−/low breast CSCs were isolated from the
MCF-7 cell line and evaluated for their resistance to
known hormonal therapy. Results demonstrated that the
breast CSC population was resistant to doxorubicin but
not to tamoxifen [71]. Research undertaken by Takaish
and colleagues identified a subpopulation of CD44+ cells
within gastric cancer cell lines with stem cell properties,
such as self-renewal ability and capacity to generate
differentiated progeny, and increased resistance to
chemo- and radio-therapy. This CD44+ population had
tumorigenic potential both in vitro and in vivo, unlike
CD44- cells [15]. Special care should be applied when
evaluating the surface markers by flow cytometry as
their integrity might be affected by the dissociation
Fig. 2 Cancer stem cells reprogramming as an emerging tool in modelling cancer. The normal development (green arrows) denotes a passage from
a pluripotent (zygote) to a “less potent state” (terminal differentiated adult tissues). During this process, adult stem cells (ASCs) in adult tissues suffer
multiple tumorigenic “hits” that lead to the generation of “aberrantly reprogrammed” cancer cells, forced to be maintained in an intermediate degree
of cellular differentiation (black arrow). Induced pluripotency is now being employed on cancer cell lines or patients’ tumours (named induced
pluripotent cancer stem cells or iPCSCs) (blue arrows). iPCSCs cells epigenetically and transcriptionally resemble the ESC state and the cancer genome
seems to be repressed in pluripotent state. In some cases the iPCSCs may exhibit early stage phenotypes corresponding to partial expression of the
reprogrammed cancer genome, constituting in this way a live cell model to study cancer progression [69] (reviewed in [84]). Moreover, these iPCSCs
have the ability to re-differentiate (orange arrow) back to the original or a different terminal differentiated cell lineage, losing along this process their
tumorigenic and metastatic properties [110]. Alternatively, the induction to more differentiated state can occur directly from the adult tumour (in this
case “trans-differentiation”-dashed blue arrow), without the need to pass first from the pluripotent state [61]. It is important to clarify the mechanisms
controlling these transitions, as the ability to exogenously manipulate the stemness and differentiation of a tumour might hold promise as a
therapeutic strategy in the near future
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agents. When different digestive agents were compared
with regards to their effect on the presence of CD44 and
CD24 surface markers in a breast cancer cell line, differ-
ences were observed. Indeed, enzymatic digestion affects
the identification of CSCs by flow cytometry; trypsin be-
ing more aggressive when compared to accutase [116].
Enzyme-free buffers or special tissue engineered surfaces
coupled with temperature reduction could be considered
as a replacement.
In addition to cell surface markers, the activity of intra-
cellular enzymes, such as ALDH, can be used to enrich
CSCs. The stem cell marker ALDH, a detoxifying enzyme
highly expressed in stem cells [117], has been commonly
used in the identification of CSCs. Charafe-Jauffret and
colleagues (2009) evaluated several breast cancer cell lines
to conclude that the majority were ALDH+ and that this
cell population possessed CSC properties [80]. Similar re-
sults were obtained for LSCs in AML [118] and malignant
breast stem cells in breast cancer [119].
The fluorescent dye exclusion, or side population (SP)
phenotype, is another property of stem cells that can be
used to identify CSCs. Cells that extrude fluorescent dyes
such as Hoechst 33342 are defined SP cells and can be
easily identified by the flow cytometry technique. This
characteristic is related to the high expression levels of
ABC transporters family members, such as ABCG2 trans-
porter. When the SP approach is applied to cancer cells,
stem-like cells with tumorigenic abilities and resistance to
chemotherapy are obtained [77, 78]. Indeed, ABC drug
transporters have been shown to protect CSCs from che-
motherapeutic compounds, a characteristic that could be
useful for the development of new therapies against these
transporters. Huang et al. (2009) identified in human
esophageal carcinoma cell lines a subpopulation of cells
with CSC properties with higher tumorigenicity, when ap-
plying the SP assay [76]. Similar results were obtained in
glioma [72], ovarian [73], and pancreatic [74] cell lines. Al-
though SP+ cells were showed to be more tumorigenic
when compared to SP- cells, ABCG2+ and ABCG2- cancer
cells were shown to be similar [75].
An effective method to isolate CSCs is based on
their resistance to anoikis. Anoikis is a type of pro-
grammed cell death, which is activated when cells de-
tach from the surrounding extracellular matrix. This
process prevents the growth of adherent-independent
cells. The resistance to this mechanism may explain
cancer progression and metastasis [120]. For this rea-
son the selection of cells resistant to anoikis may be
used as an assay to obtain CSCs. Harrison et al.
(2010) reported that anoikis resistant cells from breast
cancer cell lines and primary human tumours were
mainly ESA+CD44+CD24low with self-renewal and
tumorigenic properties in vitro and in vivo, therefore
classified as breast CSCs [79].
Other approaches use specific culture conditions to
obtain CSCs such as selection through i) chemotherapy
enrichment, ii) growth of stem cells in media derived
from cancer cell lines, iii) suspension culture, and iv) re-
petitive cycles of hypoxia and reoxygenation, among
other techniques. Lu and Labhasetwar (2013) established
a drug resistant MCF-7 cell line obtained after a long
period of treatment with doxorubicin. The resultant cells
were described to have CSC characteristics [121]. Tang
and colleagues (2011) observed that methotrexate-
resistance osteosarcoma cells exhibited SP phenotype,
expressed CSC markers and were more tumorigenic
when compared to parental cells [122]. When mouse
breast cancer cells were treated with pacilitaxel and epir-
ubicin in serum-free condition and then maintained in
suspension culture, they became mostly CD44+CD24-
cells together with higher tumorigenic potential [123].
Instead of long-term drug treatment, the group of Seno
(2012) hypothesized that CSCs may be generated when
stem cells are subjected to the influence of a tumour
microenvironment. Indeed, when mouse iPSCs were
maintained in media derived from a lung cancer cell
line, cells with CSC-like properties appeared. Cells were
described to be tumorigenic when injected in vivo, to
possess the ability to self-renewal, and to express stem
cell markers [83].
A variety of 3D in vitro sphere forming assays have
been developed in order to obtain cancer stem-like cells.
These in vitro assays involve mainly sphere formation in
low-adherent stem cell culture conditions, a model de-
scribed as tumourspheres. Often stem-like cell culture
conditions include the growth of cells in low-density
conditions, to avoid cell aggregation, in media supple-
mented with epidermal growth factor (EGF), hydrocorti-
sone, insulin, progesterone, and/or heparin in the
absence of foetal bovine serum (FBS) [124]. This system
has been employed to identify cells with self-renewal
and differentiation abilities and therefore to enrich
CSCs, as described already for liver [125], pancreatic
[126], and oesophageal [127] CSCs. This type of assay
displays some disadvantages as it may require specific
culture conditions and components, otherwise CSC dif-
ferentiation or expansion limits may occur. Furthermore,
this system does not fully reproduce the tumour from
which the cells are derived, especially its structure and/
or microenvironment [46]. In addition to the identifica-
tion of cancer stem-like properties, the tumourspheres
were proved to be resistant to chemotherapy and
tumorigenic [127]. This technique presents some disad-
vantages, including the low number of successfully iso-
lated CSCs, spontaneous differentiation, and apoptosis
[128, 129]. Louie et al. (2010) developed a system to en-
rich CSCs without genetic modification based on the hy-
pothesis that repetitive cycles of hypoxia/reoxygenation
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may increase this cell population. When this system was
applied to breast cancer cell lines, a stem-like cell popu-
lation developed high tumorigenesis [130].
Strikingly, some groups have used normal somatic
cells, rather than cancer cells, to generate CSCs. In a re-
cent article by Nagata and co-workers [81] a new
method was described. CSCs were originated through
the overexpression of OSKM in human somatic fibro-
blasts. According to this method, induced pluripotent
cancer stem-like cells (iCSCs) with self-renewal and
pluripotency properties were established through the
transduction of exogenous OSKM followed by selection,
after embryoid body formation and serial transplantation
in immunodeficient mice [81]. Scaffidi and Misteli
(2011) generated CSCs from human fibroblasts through
the expression of telomerase and oncogenic H-RasV12
mutant and concomitant inhibition of p53 and pRB. The
multipotent SSEA-1+ cells generated in this process gave
rise to hierarchically organized tumours composed of
non-tumorigenic SSEA-1- cells [82].
Clinical applications of CSCs
Introduction
The currently held theory regarding the abundance of CSCs
within a given tumour, although challenged within the stud-
ies of Quintana and others, is that is generally very low
(<0.1 %) [47, 131, 132]. Given that this population displays
high resistance to selected applied therapies, a successful
clinical response would come from therapies aiming to
omit specifically these rare cells responsible for repopulat-
ing the tumour. By targeting the rapidly dividing cancer
cells of the bulk tumour, classic chemotherapy is incapable
of defeating the low-cycling CSCs. This explains cases
where there is an initial visible decrease of primary tumour
size as a response to treatment followed by further tumour
relapse. A recent study demonstrated that CSCs can be
even stimulated by chemo- or radio-therapy, and this was
reflected by the higher percentage of CD44+CD24- breast
CSCs after therapy [133]. It would be perhaps more effect-
ive to establish combination of therapies that can target
both cancer cells and CSCs [134].
Development of CSC-specific therapies
As stated above, normal stem cells and CSCs have many
properties in common . Therefore, in order for therapies
to have a future translational impact, it is important that
current research focuses on the identification of CSC-
specific properties and of new agents that could be CSC-
selective. A study published in 2012 by the group of
Bhatia presented a neoplastic hiPSC differentiation sys-
tem for compound screening of small molecules known
to induce cell differentiation [134]. The authors identi-
fied thioridazine, a clinically approved drug designed to
antagonize dopamine receptors expressed on CSCs, as
neoplastic cell- and CSC-specific without affecting nor-
mal stem cells, demonstrating at the same time the use
of differentiation as a therapeutic strategy. In another
line of studies, clinical data were recently presented at
the 2015 American Society of Clinical Oncology (ASCO)
annual meeting in Chicago regarding the development
of two novel compounds, BBI608 and BBI503, orally-
administered, which are designed to target CSC path-
ways in multiple tumour types. BBI608 targets STAT3,
leading to inhibition of the critical genes for maintaining
cancer stemness. It was also shown to enhance anti-
tumour activity when administered with classic chemo-
therapy in gastric and colorectal cancer. BBI503 inhibits
Nanog and other cancer stem cell pathways by targeting
kinases, and showed encouraging early signs of anti-
cancer activity for patients with advanced colorectal can-
cer [135]. To date, many CSC-limited therapies based on
identified CSC-specific properties have been proposed,
many of which hold promise for clinical therapy. Table 2
categorizes these CSC-specific therapies.
Therapies targeting the CSC microenvironment/niche
The CSC microenvironment is now considered a hot
target field in CSC therapy. The idea would be to simply
disturb the supportive microenvironment that can feed
and support the CSCs population. Niches are the most
widely studied microenvironments, defined by a variety
of cell types such as cancer associated fibroblasts
(CAFs), tumour associated macrophages (TAMs),
tumour endothelial cells (TECs), mesenchymal stem
cells, immune and endothelial cells lining across the
tumour vasculature, cell-cell contacts, extracellular
matrix (ECM), and soluble factors such as growth fac-
tors and cytokines [136]. Although normal and tumour
niches differ in many aspects, manipulation of the con-
ditions of the tumour/metastatic niche may modulate
the cancer stem cell frequency, survival and potency.
Stromal incompatibility can influence the number of
CSCs in human tumours by dramatically affecting the
survival of the engrafted human cells within the host,
which may be mitigated when humanized mouse models
(NSG) are used. Kuperwasser and colleagues (2004), in
an effort to reconstruct the human mammary gland
within mice, showed that both stromal and epithelial
components are necessary for the development of the
xenografts in vivo, whereas genetic manipulation of the
stromal cells prior to transplantation resulted in the
growth of neoplasias. These mouse models, which man-
age to recapitulate the biological features of patients’
samples, not only provide a unique way to study the
steps of cancer pathogenesis in vivo, but also hold prom-
ise for individualized cancer therapy, allowing the pre-
diction of patients’ response to clinically tested
anticancer regimens [49].
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Table 2 Selected clinical therapeutic agents in current cancer stem cell drug treatment
Target Name of drug (synonyms) Mechanism of action Ref.(s)
Microenviroment/
Niche
Anti-CD44 monoclonal Abs CD44 activation [249]
Oblimersen sodium (G3139) Bcl2 antisense oligonucleotyde [250]
AT-101 (gossypol) Bcl2, Mcl1 inhibitor [251, 252]
ABT-263/ABT-737 Pan Bcl2 inhibitor [253]
Obatoclax (GX15-070) [254]
Sabutoclax (Bl-97C1) [255]
Anti-integrin alfa 6 monoclonal Abs Block integrin alfa 6 binding [256]
GLPG0187 Integrin alfa peptide antagonist [257]
EMD 121974 (Cilengitide) Integrin alfa beta peptide antagonist [258, 259]
Volociximab Monoclonal antibody targeting integrin
alfa beta
[260]
ATN-161 Integrin alfa beta peptide antagonist [261]
Pepducins CXCR4 antagonist [262]
Plerixafor (AMD3100) [263]
Neutralizing ab CXCR4 blocker [264]
Bevacizumab (Avastin) VEGF-A/VEGFR blocker [151, 265]
Cediranib/AZD2171 Tyrosine kinase inhibitor VEGFR2 [152, 266]
EphA3 monoclonal Abs EphA3 blockers Clinical trial phase I by KloBios
Pharmaceuticals
Systemic infusion of enzyme PEGPH20 HA inhibitor [156]
Anthracyclines, EGFR inhibitors, cardiac
glycosides, histone deacetylases, HSP90
inhibitors, microtubule targeting agents,
proteasome inhibitors, topoisomerase
I inhibitors
HIF-1 inhibitors Reviewed in [158]
DNA vaccines Legumain, Fra-1, Stat3, FAP, HER-2
(CAFs-TAMs)
Reviewed in [138]
Monoclonal Ab Sibrotozumab FAP Clinical trial phase I [267]; [139]
PAI-1 uPA/uPAR inhibitors Reviewed in [137]
Radioactive labeled Ab, siRNA Tenascin-C Reviewed in [137]
Monoclonal Ab 81C6 Clinical trial phase II [267]; [147]
NK4, anti-HGF mAbs HGF/Met [142, 143]
5-Aza-2΄-deoxycytidine DNMT1 [140]
MMPs inhibitors MMPs [141, 268]
Wnt/βcatenin
pathway
Anti-Frizzled (Fzd7) monoclonal
antibodies (OMP-18R5)
Block formation of active receptor
signalling complex; binds 5 Fizzled
receptors
Clinical trial phase I by OncoMed; [159,
267]
Truncated Fizzled 8-Fc fusion
protein (OMP-54 F28)
Fzd8-Fc selectively binds Wnt ligands Clinical trial phase I by OncoMed in
collaboration with Bayer Pharma AG
NSAIDs COX mechanisms [269, 270]
IWP2 o-acetyltransferase inhibitor [271]
XAV939 Tankyrase inhibitor [272]
PKF115-584 TCF/βcatenin inhibitor [273]
CGP049090
IWR Axin stabilizer [271]
ICG-001 CREB/βcatenin interaction inhibitor [274]
Hedgehog pathway GANT-61 Gli DNA binding inhibitor [173]
Arsenic trioxide [174]
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Table 2 Selected clinical therapeutic agents in current cancer stem cell drug treatment (Continued)
BMS-833923 (XL139) SMO inhibitor [267]
LDE-225
LEQ506
PF-04449913
TAK-441
Cyclopamine and based compounds [170]
Vismodegib (GDC-0049) [275]
mTOR/PI3K/Akt Perifosine (krx-0401, d-21266) Akt inhibitor [276]
MK-2206 [277]
GSK690693 [278]
GSK2141795 [279]
LY2780301 [280]
Rapamycin mTORC1 inhibitor [281]
Temisirolimus (CCl-779) [282]
Everolimus (SDZ RAD) [283]
Ridaforolimus (AP23573, MK-8669) [284]
OSI-027 mTORC1/2 inhibitor [285]
PP242 [286]
PP30
WAY-600 [179]
WYE-687
WYE-354
AZD8055 [287]
INK128 [288]
NVP-BKM120 PI3K inhibitor [289]
PX-866 [290]
GDC-0941 [291]
CAL-101 (GS-1101) [292]
SF1126 PI3K & mTOR inhibitor [293]
NVP-BEZ235 [294]
XL765 [295]
GDC-0980 [296]
PI-103 [297]
Metformin Inhibition of mTOR activation
through AMPK
[181]
Notch pathway Anti-Notch 2 and 3 monoclonal
Abs (OMP-595R)
Block cleavage of Notch receptor Clinical trial phase I by OncoMed
Anti-Notch 1 and 2 monoclonal Abs [298]
Anti-Notch 3 monoclonal Abs [299]
Anti-DLL4 (demcizumab) Block binding of DLLL4 to
Notch receptor
Clinical trial phase I by OncoMed
Anti-DLL4 monoclonal Abs
(OMP-21 M18, REGN421)
[160, 267]
DAPT Gamma-secretase inhibitor [300]
MRK-003 [301]
LY450139 [302]
Telomerase Imetelstat/GRN-163 L Telomerase inhibitor
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CAFs, TECs, and TAMs are fundamental components
of tumour microenvironment, whose role is critical in car-
cinogenesis and for this reason have attracted a lot of at-
tention as potential targets of tumour microenvironment
(reviewed in [137]). CAFs overexpress specific therapy tar-
gets such as legumain, an asparaginyl endopeptidase,
proto-oncogene Fra-1, transcription factor Stat3, fibro-
blast activation protein (FAP) as well as HER-2. The devel-
opment of DNA vaccines directed against some of these
targets resulted in the elimination of tumour growth, pro-
gression, metastasis and recurrence in mouse tumour
models (reviewed in [138]). FAP, a protein that may play a
role in the differentiation of fibroblasts to myofibroblasts,
can be inhibited via a monoclonal antibody, sibrotuzumab
has shown to be promising in early clinical trials [139].
Another approach for CAF-targeted therapy would be the
use of drugs that inhibit differentiation of stromal cells
into activated CAFs, such as the use of the DNA demethy-
lating agent 5aza-dC (5-aza-2΄-deoxycytidine) to inhibit
myofibroblast differentiation from hepatic stellate cells
[140]. In addition, certain epithelial cell derived matrix
metalloproteinases (MMPs) (i.e. MMP 7, 9, 2 and 3) may
play a role in myofibroblast differentiation and in ECM re-
modelling. MMPs can be targeted in therapy using MMP
inhibitors like TIMP-2 [141]. A third approach would be
stroma-directed therapies against growth factors, secreted
by activated CAFs, which act on epithelial transformation
and enhance invasiveness. For example, the hepatocyte
growth factor (HGF/Met) pathway has been used as a tar-
get in early pre-clinical studies using NK4, a competitive
antagonist of Met and anti-HGF monoclonal antibodies
[142, 143]. Another CAF-derived factor, the urokinase
plasminogen activator (uPA) and its receptor (uPAR) and
their mediated signalling have been implicated in tumour
cell invasion, survival, and metastasis in a variety of can-
cers. Inhibitors of uPA and radioactive labelled PAI-1 have
shown efficacy in inhibiting tumour growth and invasion
in pre-clinical studies of pancreatic and prostate cancers
[144, 145] (reviewed in [137]). Tenascin-C, another target
of therapy abundantly expressed in CAFs, binds to cell
Table 2 Selected clinical therapeutic agents in current cancer stem cell drug treatment (Continued)
Clinical trial phase II by Geron
Corporation; [216]
GRN-163 Antagonist of telomerase template [303]
Drug efflux PSC-833 ABCB1 inhibitor [304]
YHO-13351 ABCG2 inhibitor [305]
Redox balance and
metabolism
Genipin Suppression of UPC2 [228]
Phytochemicals Redox system [225, 226]
Indo-3-carbinol (I3C) Redox system (stimulates BRCA1)
Genistein Redox system (ROS scavenger, inhibitor
of NFkB, Akt, PTK)
[227]
CSC immunogenic
responses
CD133 peptide, ICT-121 Dendritic cell-based vaccine Clinical trial phase I by ImmunoCellular
Therapeutics
Peptide vaccine (SL401 and SL701) Interleukin-3 receptor Clinical trial phase I and II completed by
Stemline Therapeutics
VS6063 Focal adhesion kinase (inhibitor) Clinical trial phase I completed by
Verastem and Pfeizer
Ipilimumab CTLA-4 blockers Clinical trial phase III by BMS/Medarex;
[306]
TGN1412 CD28 agonist Clinical trial phase I [267]; [307]
MDX-1106 PD-1 antagonist Clinical trial phase I [267]; [308]
Celebrex, Rofecoxib COX2 inhibitors Reviewed in [209]
CXCR1 blocking Abs or small
molecule repertaxin
IL-8/CXCR1 inhibitor [210]
TGF-β type II receptor antibody
or SMAD4 siRNA
TGF-β/SMAD 4 [211]
Stemness BBI608 STAT3 inhibitor Clinical trial phase III [135]
BBI503 Nanog inhibitor
miRNA based
therapies
let-7 anti-sense oligos H-RAS and HMGA2 [197]
miR200c Bmi-1, ZEB1 [199–201]
miR-34a CD44 activation [202]
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surface receptors and ECM components and has been
known to promote colon cancer metastasis in response to
TGF-β signalling [146]. Tenascin-C inhibitors and the
monoclonal antibody 81C6 have been shown to be effect-
ive in early clinical trials in astrocytomas and Non-
Hodgkin’s lymphoma [137] and in brain tumours [147],
respectively. The CAFs-related connective tissue growth
factor (CTGF) holds a therapeutic promise. Aikawa et al.
(2006) developed a fully humanized CTGF-specific mono-
clonal antibody, FG-3019, as a novel therapeutic approach
for pancreatic ductal adenocarcinoma. FG-3019 decreased
the volume of intra-pancreatic tumour and attenuated its
metastatic potential [148].
The prevention of the growing vascularisation in the
tumour can be used as a CSC-target therapy. Vascular
endothelial growth factor (VEGF), a molecule that dir-
ectly supports the development of local vasculature, is
the target of bevacizumab [149]. When glioma and me-
dulloblastoma were treated with this inhibitor, a deple-
tion of CSCs was observed, demonstrating that VEGF is
a relevant target for CSCs [150]. Promising results of
anti-angiogenesis therapy have been reported in clinical
trials for bevacizumab [151] or cediranib (AZD2171, a
VEGFR inhibitor) [152]. Interactions with the stromal
microenvironment can alter the survival pathways that
are activated in CSCs. One example might be the culture
of pro-survival proteins, like Bcl-2 and Bcl-XL with
CD34+ leukaemia CSCs, thus diminishing apoptosis after
chemotherapy [153]. In addition to VEGF inhibitors, a
high number of Bcl-2 family inhibitors are currently in
preclinical and clinical drug development [154].
An anti-EphA3 antibody, currently in phase I trial, of-
fers another potential therapy acting on the microenvir-
onment. EphA3 was found to be expressed in the preB
leukaemia cell line and in a subset of samples from pa-
tients with leukaemia [155]. Although no direct link was
found between EphA3 expression and LSCs, studies have
shown that anti-EphA3 may act against CSCs, since its
incubation with preB leukaemia cells leads to the loss of
the CSC’s in vitro ability to form colonies. In a study by
Provenzano et al. (2012), when an enzyme (PEGPH20)
targeting hyaluronic acid (HA) is systemically delivered
with standard chemotherapy it can permanently remodel
the tumour microenvironment and achieve better anti-
tumour responses, resulting in a near doubling of the
overall survival [156]. A detailed list of drugs targeting
various components of the niche is listed in Table 2.
The hypoxic niche is another area of significant inter-
est. The slow proliferation or quiescence that normal
stem cells exhibit under low O2 conditions resembles
that of cancer stem cells’ genetic-epigenetic adaptation
to the hypoxic conditions in the centre of a poorly vas-
cularised and oxygenated tumour. The brain CSCs,
which reside in low oxygenated perivascular niches
inside the bulk tumour, were shown to be specifically in-
creased by hypoxia [149]. A hypoxic niche for glioma
cells was described by Jeremy Rich’s laboratory showing
that hypoxic conditions resulted in reprogramming of
CD133- cells to CD133+ with enhanced CSC-phenotype
[157]. A major mechanism mediating the adaptation to
hypoxia is the activity of transcription factor HIF-1.
Existing pharmacological data demonstrate the anti-
cancer effects of HIF-1 inhibitors and drug-efflux pump
inhibitors, as monotherapy and/or as sensitizers to
chemotherapy in mouse models of human cancer [158].
Therapies targeting central signalling pathways of CSC
survival
Other drug candidates may target the Wnt, mTOR/
PI3K/Akt, or Notch pathways, involved in both CSC and
adult stem cell signalling [159, 160]. The Wnt pathway
plays a central role in a whole spectrum of different de-
velopmental processes, including cell proliferation and
migration, being crucial in cell fate and tissue patterning
[161, 162]. It is already known that the Wnt pathway is
involved in the self-renewal of both normal and cancer
stem cells. Indeed, aberrant Wnt signalling was observed
in the CSC population from many tumour types [161].
The high number of Wnt isoforms and the complicated
mechanism of the Wnt pathway may explain why most
of its inhibitors are still in the preclinical stage. Extirpa-
tion of CSCs by Wnt-selective drugs without depleting
the normal haematopoietic stem cells (HSCs) in G1
phase, cells depending on the Wnt pathway, might be
limited. Instead, the non-steroid anti-inflammatory
drugs (NSAIDs), indomethacin or sulindrac, have been
proved to act on the Wnt/βcatenin pathway [163, 164],
as have the second generation cyclooxygenase 2 (COX2)
inhibitors like celecoxib [165]. Lately, a downregulation
of the Wnt inhibitory factor 1 (WIF1) as a widespread
event in salivary gland carcinoma ex-pleomorphic aden-
oma (CaExPA), has been described [163, 166]. WIF1
downregulation occurs in the CaExPA precursor lesion
pleomorphic adenoma (PA) and indicates a higher risk
of progression from benign to malignant tumour [166].
Most importantly, WIF1 significantly diminished the
number of salivary gland CSCs and the anchorage-
independent cell growth. Consistent with this observa-
tion, WIF1 caused a reduction of the expression of pluri-
potency and stemness markers as well as the adult stem
cell self-renewal and multi-lineage differentiation
markers WNT3A, TCF4, c-Kit, and Myb [166]. Detailed
names and corresponding references of candidate drugs
targeting the Wnt pathway are listed in Table 2.
The Hedgehog (HH) pathway is involved in the main-
tenance and regeneration of adult tissues, through the
regulation of adult stem cells, as well as in cancer develop-
ment through the regulation of CSCs [167]. Currently
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three mammalian HH ligands have been identified, of
which Sonic HH (SHH) is the best described and studied.
In the absence of HH ligand, its receptor called Patched
(Ptch) represses Smoothened (SMO). Binding of HH
removes this repression, allowing SMO to activate Gli
family of transcription factors and other targets [168].
Although the HH pathway can be activated at several
different points, most drugs target the SMO transmem-
brane protein. The first inhibitor to be identified was
cyclopamine, which directly binds to SMO to efficiently
block the HH pathway and decrease CSCs number in
preclinical models [169, 170]. Unfortunately, the use of
cyclopamine is limited due to its low oral bioavailability
and pharmacokinetics [171]. The first clinically approved
antagonist of HH is vismodegib (GDC-0049). Several
more small molecules are currently being clinically
tested like PF-04449913 or TAK-441 among others
(Table 2). The HH pathway can also be a target by up-
stream ligands or by downstream effectors. Antibodies
targeting SHH have been shown to inhibit the clono-
genic potential of CSCs [172]. Inhibitors of Gli transcrip-
tion factors, such as the Gli DNA binding inhibitor
GANT-61 [173] and arsenic trioxide [174], may signifi-
cantly reduce self-renewal in tumours with mutations
that are located downstream of SMO, or which simply
acquire resistance to SMO-targeted molecules.
The mTOR/PI3K/Akt pathway is another known CSC
therapeutic target as it has been shown to be especially in-
volved in the generation and survival of leukaemia [175].
Many different mTOR inhibitors were already developed
and tested, including rapamycin itself and rapamycin-
related drugs (e.g. CCI-779 and RAD001). Although these
molecules were shown to inhibit CSC self-renewal [176],
clinical use had limited success [177, 178]. Meanwhile,
novel ATP-competitive inhibitors that can target both
mTORC1 and mTORC2 complexes have been tested
[179]. Alternatives are a combination of different mTOR/
PI3K/Akt inhibitors that have been proven to be effective
in CSCs and some of them are currently in phase 1 of
clinical trials. Gemcitabine, a nucleoside analogue used in
chemotherapy, when combined with rapamycin signifi-
cantly reduced the percentage of pancreatic CSCs in vitro
obtained from primary patient samples [180]. An alterna-
tive therapeutic candidate of mTOR inhibitors is metfor-
min, a well-known drug for the treatment of type 2
diabetes. Metformin blocks mTOR through AMPK activa-
tion, important in protein synthesis, cell cycle progression,
and cell survival [181]. A combination of metformin with
chemotherapy displays prolongation of survival of breast,
lung and prostate cancers [182, 183]. Shank and col-
leagues (2012) observed an inhibition of ovarian CSCs
growth in vitro caused by metformin, dissimilar to what
was observed in vivo. However, when combined with cis-
platin, a chemotherapeutic drug tested in different types
of cancer, a restriction of the tumour growth in vivo was
observed [184]. Detailed names and corresponding refer-
ences of candidate drugs targeting the mTOR/PI3K/Akt
pathway are listed in Table 2.
Notch signalling, another stem cell-supporting path-
way, is activated in many human cancer types and its de-
regulation is related with this disease. The Notch
pathway has been reported to play an important role in
the regulation of asymmetric cell fate decisions in hu-
man mammary stem cells [185]. Abnormal activation of
the Notch pathway has been observed in CSCs from
some tumours, mostly related to self-renewal mainten-
ance and resistance to therapy observed in these cells
[186]. Therefore, inhibition of the Notch signalling path-
way could be a therapeutic target for the elimination of
the CSC subpopulation [187]. Preclinical analysis in leu-
kaemia, medulloblastoma and breast cancer with the
gamma-secretase inhibitors DAPT [79, 188], GSI-18
[189, 190], and MRK-003 [191], showed selective target-
ing of CSCs and reduced tumour sizes (Table 2). More-
over, the Notch pathway could be a direct target of
miRNAs closely related to invasion and acquisition of
stem cell like properties by tumour cells [192]. More
drugs targeting different components of the Notch path-
way are listed in Table 2.
Therapies targeting CSC-miRNAs
miRNAs are relatively small noncoding RNA molecules
that serve as transcriptional and post-transcriptional re-
pressors through the binding to their mRNA targets
[193]. Taking into account that different types of cancer
have specific profiles of miRNA expression reminiscent
of their stem cell of origin [194], the application of
miRNA-based tools in cancer therapy has lately attracted
a lot of interest [193]. miRNAs appear attractive thera-
peutic targets in cancer as they may affect the expression
of multiple genes in different developmental contexts,
including regulation of critical stem cell features as well
as metastasis, EMT, and cell division. For these reasons,
many miRNAs have been successfully targeted in vivo in
mouse models with the use of specific inhibitors called
antagomiRs [195] or have been proposed as targets in
exosome biology, by either targeting the release of miR-
NAs from exosomes, or by using these “bioactive vesi-
cles” for therapeutic delivery (reviewed in [196]).
In a study on breast cancer cell lines and human primary
cancer cells let-7a miRNA, negative regulator of stemness,
was found significantly decreased in breast CSCs and in-
creased with differentiation [197]. Re-expression of let-7
miRNA in CSCs using a lentivirus construct causes a re-
duction of the CSC proliferation and mammosphere forma-
tion. Moreover it also negatively influenced the ability of
CSCs to form tumours and metastasis in mice [197]. In an-
other study of 2009, 37 miRNAs were described as being
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up- or down-regulated in CD44+CD24- breast CSCs when
compared to non-tumorigenic cells [198]. Shimono and co-
workers focused mostly on BMI1 since it is known to regu-
late normal and CSC activity [199, 200]. Exogenous miR-
200c was found to promote reduction of BMI1 protein
levels and embryonal carcinoma cells growth in vitro and
in vivo in NOD/SCID mice [199, 200]. In normal mouse
breast stem cells expression of miR-200c repressed out-
growth formation in the mammary fat pad assay [200],
while miR-200c expression in human breast CSCs blocked
tumour initiation in NOD/SCID mice [197, 201]. miR-34a-
based therapies are emerging as novel modes of therapeutic
interventions. Systemic delivery of miR-34a, which is
known to target CD44 and is usually repressed in prostate
cancer, inhibited metastasis of prostate cancer cells and
prolonged survival of mice [202].
Therapies targeting CSC-immunogenic responses
Immune tolerance is an important property of a growing
tumour. Complexed immunogenic reactions taking place
within the tumour microenvironment are responsible not
only for tumour’s survival against the immune system but
also for the enhancement of its stemness and migration
properties. In a study of Giannoni et al. (2010), IL-6 was
shown to activate the CAFs, which in turn induced EMT
and stemness of prostate cancer cells [203]. In support of
this, Iliopoulos et al. (2011) identified IL-6 as the mediator
responsible for conversion of non-stem cancer cells into
CSCs in breast and prostate cancer [204]. Therapy-
induced changes in the tumour stroma play a critical role
in determining phenotypic plasticity and may be respon-
sible for pro-malignant phenotype acquired by the
surrounding CAFs [205]. Such events give rise to a pro-
inflammatory microenvironment characterized by in-
creased expression of TNFα, pro-inflammatory cytokines,
and INFγ, which finally induce STAT3/NFkB signaling re-
sponsible to promote self-renewal in ESCs [206] but also
to mediate resistance to therapy [207]. In another study, it
was reported that mesenchymal cells in breast cancer sup-
port CSCs through a signalling loop dependent on IL-6
and CXCL7 [208].
For these reasons, many pharmaceutical companies
today aim in the targeting of CSC subpopulation based
on selected immunogenic responses. Most promising
from current clinical trials are candidates that are related
with CSC-associated proteins used as antigens to elicit
an immune response against CSCs (Table 2). Other
drugs, such PD-1 and COX2 inhibitors and CD28 ago-
nists, have been proposed as promising anti-cancer ther-
apies Some of them, like celecoxib and rofecoxib, have
both been tested in phase II clinical trials in combin-
ation with chemotherapeutic agents in patients with
NSCLC, and pancreatic, breast, and colorectal cancers
and, for the most part, have shown additional clinical
benefit beyond that observed with chemotherapy alone
(reviewed in [209]). In another study, Ginestier et al.
(2010) developed a strategy to deplete selectively breast
CSCs in preclinical models through blockade of the IL-8
receptor CXCR1 using either a CXCR1-specific blocking
antibody or repertaxin, a small-molecule CXCR1 inhibi-
tor [210]. Blockade of TGF-β/SMAD signaling pathway
by the TGF-β type II receptor antibody or SMAD4
siRNA repressed enrichment of CSCs in the triple nega-
tive breast cancer cell model [211]. Additional candidate
drugs targeting immunogenic responses of CSCs have
been proposed and some of them have reached the clin-
ical phase (Table 2).
Therapies targeting telomeres and telomerases
Another example of CSC-specific targets is telomeres and
telomerases. Regions of repetitive nucleotide sequences
called telomeres protect the end of the chromosomes
from being recognized as double-strand breaks by the
DNA repair system [212]. Classic stem cells display consti-
tutive activity of telomerase, an enzyme that adds DNA
sequence repeats to the telomere regions, and its presence
in cancer cells can be a reflection of an origin of those
cancers from stem/progenitor cells and the imposition of
maturation arrest [213]. Compared to normal stem cells,
cancer stem cells express higher levels of telomerase
[214]. Based on that, telomerase could be a relevant target
in CSCs without destroying healthy stem cells. The most
common approach to target telomerase activity is im-
munotherapy and the use of oligonucleotide-based hTERT
inhibitors [215], both listed in Table 2. Widely studied tel-
omerase inhibitors are GRN163 and a more potent lipid
attached derivative, GRN163L (imetelstat) [216]. The tel-
omerase specific drugs lead to the reduction in the self-
renewal capacity of treated CSCs as assessed by in vitro
sphere formation [217] (Table 2). One telomerase related
drug imetelstat, was shown to block replication of glio-
blastoma CSCs and to decrease tumour growth [218]. Fur-
thermore, telomerase inhibitors are expected to target also
the bulk of the tumour. Treatment of glioma, neuroblast-
oma, lung and prostate CSCs with imetelstat induces re-
duction in the self-renewal capacity of these cells as
assessed by the in vitro sphere formation. Another finding
was that this drug displays effective properties against
xenograft tumours and reduced the number of CSCs
remaining in treated tumours [218].
Therapies targeting CSC redox balance and metabolism
Another feature that characterizes CSCs and has been
under investigation for clinical targeting is the redox bal-
ance. Oxidative stress refers to a condition of the cell char-
acterized by an excess of reactive oxygen species (ROS)
[28]. ROS, such as superoxide, hydrogen peroxide, and
peroxynitrite, are physiological byproducts of mammalian
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metabolism, and in excess may cause cell damage by oxida-
tion and nitration of macromolecules, such as DNA, RNA,
proteins, and lipids [219]. A cell generally undergoes apop-
tosis when ROS levels are high or goes into senescence at
sublethal levels [220]. In turn, ROS may play a role in cell
proliferation, differentiation, and apoptosis through the
control of signalling pathways [221].
The subsistence of the redox status is important for
normal stem cells to avoid cellular differentiation, to
maintain long-term self-renewal and to decrease the ac-
cumulation of DNA damage [28, 222]. This is indicated
by the general low levels of ROS in normal stem cells
compared to their differentiated progeny, as shown in
normal HSCs and progenitors, central nervous system
stem cells and normal breast stem cells [223, 224]. The
resistance to oxidative stress is regulated by the ROS
scavenging system that is upregulated in these cells. Cel-
lular redox status is maintained by several intracellular
redox-regulating molecules, including thioredoxins
(TRX), and glutathione (GSH)/glutaredoxin (GRX). Mol-
ecules or enzymes that can destabilize the redox status
of cancer cells will be beneficial for actually killing them.
In fact, the combination of chemotherapy with cellular
redox system modifiers has shown promising results in
clinical trials. For example targeting redox system with
phytochemicals, natural substances derived from vegeta-
bles, fruits and spices, is another method described as
being capable of intervening in carcinogenesis, which
has already reached clinical trials both in combination
with, and without, conventional chemotherapy [223]. In
another study, a phytochemical from cruciferous vegeta-
bles, the indole-3-carbinol (I3C), was associated with a
reduced risk of several tumour types, such as breast and
prostate cancers. In the acidic environment of the stom-
ach, I3C undergoes hydrolysis to a number of products,
including a dimeric product, 3,3'-diindolylmethane
(DIM). Both of these phytochemicals stimulate BRCA1
in breast and prostate cancer cells and have been shown
to protect cells against oxidative stress mediated by
H2O2 and γ-radiation [225, 226]. Another natural sub-
stance, genistein (4,5,7-trihydroxyisoflavone), which was
identified as the predominant isoflavone in soybean
enriched foods, has been shown to inhibit prostate car-
cinogenesis in animal models. Genistein has antioxidant
effects and protects cells against ROS by scavenging free
radicals, inhibiting the expression of stress-response re-
lated genes [226]. Furthermore, genistein is a powerful
inhibitor of NFkB, Akt and PTK signalling pathways, all
of which are important for cell survival [227].
Moreover, since mitochondria are the main source of
ROS, its limitation can be achieved by switching meta-
bolic pathways from oxidative phosphorylation to aer-
obic glycolysis, a phenomenon known as the “Warburg
effect”, which is characteristic of normal and CSCs. The
mitochondrial uncoupling enzymes UCP2 are considered
responsible for this metabolic change and this is the
main reason why they are in the focus of drug develop-
ment. Suppression of UCP2 by genipin, a plant derived
small molecule, was shown to suppress tumorigenic
properties of breast cancer cells, mediated by a decrease
of ROS and downregulation of UCP2 [228].
Biomarker discovery and cancer clinical diagnostics
In order to reduce the rate of adverse clinical outcome
among patients, it is very important to detect cancer in
early stages as well as to identify which patients are
more likely to benefit from available therapies. In this
way, identification of biomarkers and their application in
the screening of cancer are of enormous importance as
they would allow proper detection and prognosis of can-
cer [229]. Biomarkers, molecules found in tissues or
fluids within the body of an individual and related with a
disease [230], can be either DNA, RNA, miRNA, epigen-
etic modifications or protein expression [51]. Biomarkers
may be used to detect cancer, risk assessment, distinc-
tion between benign and malignant forms of cancer, dis-
ease status, response to therapy, tumour recurrence and
many other applications [231]. Kim et al. (2013) devel-
oped an in vivo model of pancreatic cancer at an early
stage of the disease that can be advantageous in the
identification of biomarkers related with this phase of
the disease and applicable to disease monitoring after
therapy [69]. Three month old teratomas, generated
from the injection of reprogrammed human pancreatic
ductal adenocarcinoma (PDAC) cells into immunodefi-
cient mice, exhibited pancreatic intraepithelial neoplasia
(PanIN) structures and marker expression related to the
early stage of the disease. When teratomas were ob-
served 6-9 months after injection, a progression to inva-
sive stage of human pancreatic cancer was detected.
Indeed, proteins collected from the serum-free media
and analysed by nanoLC/MS/MS enabled the identifica-
tion of secreted or released proteins associated with the
activation of HNF4α specific to the late PanIN stage
[69]. This discovery can be used as a tool in the diagnos-
tics and disease monitoring after therapy of pancreatic
cancer.
Recent technological advances have allowed the possi-
bility to analyse the characteristics of circulating exo-
somes and microvesicles secreted by CSCs for cancer
detection and monitoring. Exosomes, small endocytic
membrane-derived vesicles important for cell homeosta-
sis and cell-to-cell communication present in most bod-
ily fluids, can harbour a variety of proteins, nucleic acids,
and lipids. Exosomes can merge with and release their con-
tents in recipient cells and can exhibit a broad range of
functions, can mediate adaptive immune responses to path-
ogens and tumours, promote tumorigenesis, angiogenesis,
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and metastasis, and can determine response to therapy by
transferring oncogenes and onco-miRNAs between cancer
cells or between the tumour and its stromal environment.
Exosomes are very stable and due to their phospholipid bi-
layer protect their contents from degradation by nucleases
and proteases. Consequently, biomarkers at a relatively low
expression are much easier to be detected through isolating
exosomes. For instance, some biomarkers such as PCA3
and TMPRSS2 are mRNAs not easily detected in body
fluids, but appear in exosomes in prostate cancer [232].
CD63+ exosomes were significantly increased in
plasma of melanoma patients compared to healthy con-
trols [233], while in a comparative analysis, CD63 was
found enriched in exosomes derived from malignant
cancer cells compared to those derived from non-cancer
cells [234]. In another study, glioblastoma-specific epi-
dermal growth factor receptor vIII (EGFRvIII) was found
in serum exosomes from a significant proportion of pa-
tients, whereas EGFR, EGFRvIII, and TGF-β were found
in serum exosomes from patients with brain tumours,
suggesting that they all might provide diagnostic infor-
mation for glioblastomas and brain tumours respectively
[235, 236]. Since 2009, when it was reported that miR-
NAs, previously demonstrated as diagnostic markers for
ovarian cancer, were found at similar levels in biopsy
specimens of ovarian cancer and serum exosomes iso-
lated from the same ovarian cancer patients, many cases
of exosomal miRNAs have been proposed for cancer
diagnostics. Brase and coworkers showed that serum
levels of miR-141 and miR-375 correlate with tumour
progression in prostate cancer [237]. Moreover, the exo-
somal miR-21 level was found elevated in serum from
patients with esophageal squamous cell cancer (ESCC)
versus serum from patients who have benign tumors
without systemic inflammation [238]. Interestingly,
Takeshita and colleagues reported that serum-derived
exosomal miRNA-1246 was a good biomarker that sig-
nificantly correlated with the metastasis stage and was
found to be a strong independent risk factor for poor
survival [239]. In a study of stage I involving PDAC pa-
tients, higher levels of exosome-resident macrophage
migration inhibitory factor (MIF) were found to predict
an increased risk of the eventual development of liver
metastasis [240].
In contrast to exosomes, which originate from endo-
somes, microvesicles are fragments that derive directly
from the plasma membrane, with a size range from
100 nm to 1 μm. The group of Camussi demonstrated
recently that microvesicles derived from CSCs can in-
duce angiogenesis and lung metastasis in vivo [241]. The
group of researchers isolated CD105+ cells from human
renal carcinoma and showed they possess CSC charac-
teristics like expression of stem cell markers, formation
of spheres in vitro, and ability to form tumours in vivo.
The CSC-derived microvesicles were CD105+ and con-
tained mRNA and miRNA. The mRNA (e.g. VEGF and
FGF2) was shown to be involved in the stimulation of
angiogenesis as confirmed by the formation of capillaries
in vivo after injection of microvesicle-treated HUVEC.
When renal tumour cells were injected together with
CSC-derived microvesicles into mice, a higher number
of metastasis was observed compared to CD105- cells
derived-microvesicle [241].
As already mentioned, CAFs do not just surround the
growing tumour passively, but are actively participating
in the establishment of a metastasis-promoting commu-
nication, influencing at the same time innate and adap-
tive immune responses. For these reasons, CAFs and
their products are now considered potential prognostic
biomarkers and candidate targets for novel therapeutic
strategies (reviewed in [242]). In CRC stage II and III, α-
smooth muscle actin (a-SMA)-expressing CAFs were
proposed as useful indicators of poor prognosis [243],
whereas the combination of calumenin with cadherin 11
expressed by CAFs displayed a significant association
with disease-free survival and overall survival [244].
Moreover, in patients with advanced colorectal adeno-
carcinomas, increased stromal FAP was considered an
adverse prognostic marker [245]. A significant correl-
ation was observed between stromal FAP-a and stromal
cell-derived factor-1 (SDF-1) mRNA levels, primarily
expressed by CAFs, after pre-operative chemo/radiother-
apy in rectal cancer patients. FAP-a and SDF-1 gene ex-
pression patterns significantly correlated with distant
recurrence and poor probability of recurrence-free and
overall survival [246]. In another study, multiplex bead
immunoassays and an enzyme-linked immunosorbent
assays were used to characterize CAFs-signatures from
52 kinds of CAFs in 68 GC patients who were treated
with fluoropyrimidine and platinum combination
chemotherapy. Serum CAF profiling was able to differ-
entiate GC patients in groups, and more importantly,
distinguishing a high 11-CAF signature could identify
GC patients with a poor prognosis when treated with
standard chemotherapy who need urgent new treatment
strategies [247]. Accordingly, Tchou and colleagues ob-
served different gene expression profiles (particularly in
pathways associated with cytoskeleton, integrin signal-
ling and metastasis) among early passage primary CAFs
derived from three main subtypes (ER+, triple negative
and Her2+) of human breast cancer samples, suggesting
that CAFs gene expression profile might be a useful
marker in breast cancer prognosis [248].
Conclusions and further directions
More and more evidence is currently supporting the
CSCs theory. It is known that CSCs play a crucial role in
cancer initiation and primary tumour sustainment.
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These cells can also facilitate the metastasis to distant or-
gans from the primary site. Based on these CSCs proper-
ties, it is obvious that they are excellent therapeutic
targets, assuming that elimination of the CSC population
will block the metastasis and eliminate the possibility of
tumour regeneration. Since not only CSCs but also stem
cells are able to protect themselves from cellular insult it
would be important to probe whether blocking either nor-
mal stem cells properties or related pathways can induce
CSC sensitivity to selected therapies. Many prevalent
treatments were founded based on stem cell pathways:
Notch, Hedgehog, or Wnt, among others. Moreover, not
only the pathways themselves, and surely not only one
single pathway, are important in order to enrich CSCs,
but many intra-microenvironmental connections, and re-
lationships between microenvironment and the tumour,
play a crucial role in enriching this subpopulation. Also a
fundamental step before directly targeting the CSC sub-
population would be characterization of the complex and
functional markers. Development of clinical trials related
to biomarker strategies would be essential to identify
proper endpoints to clinically assess therapies targeting a
minority, in most type of cancers, of tumour cells. As
already described, the CSC population is heterogeneous.
New data obtained with CSC in vitro models provided a
broadened knowledge about the nature of these cells. On
the top of that, CSCs could give us clues about the identi-
fication of stem cell pathways activated during cancer pro-
gression, which could guide further therapeutic steps and
the precise design of preclinical and clinical trials.
Although further studies are needed to explore the
relevance of CSCs in vitro models, it is certainly true
that the data based on them have a potential utility for
clinical applications. Such prospective therapies also
have significant implications for pharmaceutical com-
panies that are seeking to successfully develop a drug in
late clinical phases.
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